摘要:
A non-human transgenic animal having a polynucleotide encoding an STXBP1 polypeptide, which polynucleotide is operably linked to a promoter, wherein said transgenic animal has greater than wild-type expression of the STXBP1 polypeptide in at least one brain region, as well as related vectors, methods of producing transgenic animals, in vitro and in vivo screening methods for potential therapeutic agents, and methods for treating and diagnosing neuropsychiatric illness are disclosed.
摘要:
The present invention relates to in vitro methods and products for detecting the presence of an invasive carcinoma in an individual, for determining and/or predicting the stage and/or invasiveness of said carcinoma in an individual, or for monitoring the effect of the therapy administered to an individual who has said carcinoma based on col11a1 gene and proCOL11A1 protein expression. The invention also relates to the search for, identification, development and evaluation of the efficacy of compounds for therapy for said carcinoma, for the purpose of developing new medicinal products. The invention also relates to agents inhibiting proCOL11A1 protein expression and/or activity, and/or the effects of this expression.
摘要:
A non-human transgenic animal having a polynucleotide encoding an STXBP1 polypeptide, which polynucleotide is operably linked to a promoter, wherein said transgenic animal has greater than wild-type expression of the STXBP1 polypeptide in at least one brain region, as well as related vectors, methods of producing transgenic animals, in vitro and in vivo screening methods for potential therapeutic agents, and methods for treating and diagnosing neuropsychiatric illness are disclosed.
摘要:
The present invention refers to an in vitro method for detecting the presence of renal cancer in an individual, for determining the stage, malignancy or severity of said carcinoma in the individual or for monitoring the effect of the therapy administered to an individual having said cancer; to the search, identification, development and assessment of the efficacy of compounds for therapy for said cancer in an attempt to develop new drugs; as well as to agents inducing Plexin-131 protein expression and/or activity, or to agents inhibiting the effects of Plexin-B1 protein expression and/or activity repression.
摘要:
The present invention relates to in vitro methods and products for detecting the presence of an invasive carcinoma in an individual, for determining and/or predicting the stage and/or invasiveness of said carcinoma in an individual, or for monitoring the effect of the therapy administered to an individual who has said carcinoma based on col11a1 gene and proCOL11A1 protein expression. The invention also relates to the search for, identification, development and evaluation of the efficacy of compounds for therapy for said carcinoma, for the purpose of developing new medicinal products. The invention also relates to agents inhibiting proCOL11A1 protein expression and/or activity, and/or the effects of this expression.
摘要:
The invention relates to the field of personalized therapy and, in particular, to a method for classifying a patient suffering from rheumatoid arthritis as a responder or as a non-responder patient to a treatment based on a biological drug.
摘要:
The present invention refers to a non-invasive in vitro method to detect a transitional cell carcinoma of the bladder in an individual via urine analysis, to determine the stage or severity of this cancer in an individual or to monitor the effect of treatment administered to an individual suffering from this cancer.
摘要:
The present invention refers to an in vitro method for detecting the presence of demyelinating diseases in an individual, for determining the stage or severity of said diseases in the individual, or for monitoring the effect of the therapy administered to an individual suffering said diseases; to the search, identification, development and evaluation of efficacy of compounds for therapy of said diseases for the purpose of developing new drugs; as well as to agents inhibiting DUSP6 protein expression and/or activity, and/or the effects of this expression. The methods and agents of the invention are preferably applied to multiple sclerosis.